StreetInsider.com News Articles

Ainos reports 499% revenue growth in 2025, expands AI scent technology

Mon, 08 Jun 2026 08:00:11 -0400

Ainos Inc. (NASDAQ: AIMD) released its 2026 mid-year shareholder letter, reporting 499% year-over-year revenue growth during fiscal year 2025. The company has shifted from biotechnology focus to technology platform development centered on artificial intelligence-powered scent digitization.

The Houston-based company advanced commercial deployments in semiconductor manufacturing environments during the first half of 2026. Ainos collaborated with advanced semiconductor manufacturers and strategic industry partners to expand industrial-scale scent AI datasets for environmental intelligence and safety monitoring applications.

The company expanded its scent AI technology into healthcare settings through collaborative research programs with National Taiwan University Hospital and MacKay Memorial Hospital. These initiatives focus on

Ainos reports 499% revenue growth in 2025, expands AI scent technology

Mon, 08 Jun 2026 08:00:11 -0400

Ainos Releases 2026 Mid-Year CEO Letter to Shareholders

Mon, 08 Jun 2026 08:00:00 -0400

Building the Olfactory Layer of Physical AI

Highlighting Progress Across Semiconductor Manufacturing, Healthcare Infrastructure and Physical AI Applications

HOUSTON, TX / ACCESS Newswire / June 8, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a pioneer in AI-powered scent digitization and Smell AI technologies, today released its 2026 Mid-Year Letter to Shareholders from Chairman, President and Chief Executive Officer Eddy Tsai.

2026 First Half Highlights

Commercial Momentum

Reported 499% year-over-year revenue growth during fiscal year 2025.
Continued transforming Ainos from a biotechnology-focused company into a technology platform company centered on Smell AI and Environmental Intelligence.
Updated the

Ainos Releases 2026 Mid-Year CEO Letter to Shareholders

Mon, 08 Jun 2026 08:00:00 -0400

Building the Olfactory Layer of Physical AI

Highlighting Progress Across Semiconductor Manufacturing, Healthcare Infrastructure and Physical AI Applications

2026 First Half Highlights

Commercial Momentum

Reported 499% year-over-year revenue growth during fiscal year 2025.
Continued transforming Ainos from a biotechnology-focused company into a technology platform company centered on Smell AI and Environmental Intelligence.
Updated the

Ainos Releases 2026 Mid-Year CEO Letter to Shareholders

Mon, 08 Jun 2026 08:00:00 -0400

Building the Olfactory Layer of Physical AI

Highlighting Progress Across Semiconductor Manufacturing, Healthcare Infrastructure and Physical AI Applications

2026 First Half Highlights

Commercial Momentum

Reported 499% year-over-year revenue growth during fiscal year 2025.
Continued transforming Ainos from a biotechnology-focused company into a technology platform company centered on Smell AI and Environmental Intelligence.
Updated the

Ainos Releases 2026 Mid-Year CEO Letter to Shareholders

Mon, 08 Jun 2026 08:00:00 -0400

Building the Olfactory Layer of Physical AI

Highlighting Progress Across Semiconductor Manufacturing, Healthcare Infrastructure and Physical AI Applications

2026 First Half Highlights

Commercial Momentum

Reported 499% year-over-year revenue growth during fiscal year 2025.
Continued transforming Ainos from a biotechnology-focused company into a technology platform company centered on Smell AI and Environmental Intelligence.
Updated the

Ainos expands AI Nose platform into hospital emergency departments

Fri, 05 Jun 2026 08:02:52 -0400

Ainos Inc. (NASDAQ: AIMD) announced that research firm VASRO GmbH published a report discussing the company's expansion of its AI Nose platform into emergency department operations at an Asian academic medical center.

The research program deploys AI Nose technology within a live emergency department to evaluate environmental scent analysis for overcrowding early warning and respiratory infection risk analysis. The initiative is designed to generate more than 2,500 hours of emergency department environmental data.

According to the VASRO report, this deployment expands AI Nose beyond its current applications in semiconductor manufacturing, industrial environments, and robotics into healthcare infrastructure. The platform digitizes scent into

Ainos expands AI Nose platform into hospital emergency departments

Fri, 05 Jun 2026 08:02:52 -0400

VASRO Research Highlights Ainos Smell AI Expansion into Emergency Department Operations

Fri, 05 Jun 2026 08:00:00 -0400

HOUSTON, TX / ACCESS Newswire / June 5, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a Smell AI company digitizing scent into machine-readable data for artificial intelligence applications, today highlighted a recent report published by VASRO GmbH ("VASRO"), discussing the expansion of the Company's AI Nose platform into emergency department operations and the continued growth of its Smell ID data across diverse real-world environments.

In the report, VASRO reviews Ainos' recently announced research program at one of Asia's leading academic medical centers, where AI Nose is being deployed within a live

VASRO Research Highlights Ainos Smell AI Expansion into Emergency Department Operations

Fri, 05 Jun 2026 08:00:00 -0400

In the report, VASRO reviews Ainos' recently announced research program at one of Asia's leading academic medical centers, where AI Nose is being deployed within a live

VASRO Research Highlights Ainos Smell AI Expansion into Emergency Department Operations

Fri, 05 Jun 2026 08:00:00 -0400

In the report, VASRO reviews Ainos' recently announced research program at one of Asia's leading academic medical centers, where AI Nose is being deployed within a live

VASRO Research Highlights Ainos Smell AI Expansion into Emergency Department Operations

Fri, 05 Jun 2026 08:00:00 -0400

In the report, VASRO reviews Ainos' recently announced research program at one of Asia's leading academic medical centers, where AI Nose is being deployed within a live

Ainos Launches Smell AI Study at National Taiwan University Hospital for ER Overcrowding and Respiratory Infection Risk Analysis

Mon, 01 Jun 2026 08:00:00 -0400

AI Nose Expands from Semiconductor Facilities into Frontline Healthcare Infrastructure

HOUSTON, TX / ACCESS Newswire / June 1, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a Smell AI company digitizing scent into machine-readable data for artificial intelligence applications, today announced the launch of a research program at National Taiwan University Hospital ("NTUH"), one of Asia's leading academic medical centers, to deploy AI Nose inside a live emergency department environment for intelligent environmental monitoring, ER overcrowding early warning, and respiratory infection risk analysis.

The program aims to expand Smell AI, powered by

Ainos Launches Smell AI Study at National Taiwan University Hospital for ER Overcrowding and Respiratory Infection Risk Analysis

Mon, 01 Jun 2026 08:00:00 -0400

AI Nose Expands from Semiconductor Facilities into Frontline Healthcare Infrastructure

The program aims to expand Smell AI, powered by

Ainos Launches Smell AI Study at National Taiwan University Hospital for ER Overcrowding and Respiratory Infection Risk Analysis

Mon, 01 Jun 2026 08:00:00 -0400

AI Nose Expands from Semiconductor Facilities into Frontline Healthcare Infrastructure

The program aims to expand Smell AI, powered by

Ainos Launches Smell AI Study at National Taiwan University Hospital for ER Overcrowding and Respiratory Infection Risk Analysis

Mon, 01 Jun 2026 08:00:00 -0400

AI Nose Expands from Semiconductor Facilities into Frontline Healthcare Infrastructure

The program aims to expand Smell AI, powered by

VASRO Research Highlights Ainos AI Nose Commercialization Progress and Semiconductor Industry Shift Toward AI-Driven Environmental Intelligence

Wed, 20 May 2026 08:00:00 -0400

HOUSTON, TX / ACCESS Newswire / May 20, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today highlighted a new research update published by VASRO GmbH discussing AI Nose, the Company's AI-powered scent digitization and Smell AI platform, and ongoing commercialization progress across semiconductor manufacturing, robotics integration, and healthcare infrastructure markets. The report notes that the Company is advancing initiatives intended to support potential second half 2026 revenue generation.

The VASRO report characterizes Ainos' first quarter of 2026 as a "commercialization-build quarter." According to the report, Ainos continues progressing key

VASRO Research Highlights Ainos AI Nose Commercialization Progress and Semiconductor Industry Shift Toward AI-Driven Environmental Intelligence

Wed, 20 May 2026 08:00:00 -0400

The VASRO report characterizes Ainos' first quarter of 2026 as a "commercialization-build quarter." According to the report, Ainos continues progressing key

VASRO Research Highlights Ainos AI Nose Commercialization Progress and Semiconductor Industry Shift Toward AI-Driven Environmental Intelligence

Wed, 20 May 2026 08:00:00 -0400

The VASRO report characterizes Ainos' first quarter of 2026 as a "commercialization-build quarter." According to the report, Ainos continues progressing key

VASRO Research Highlights Ainos AI Nose Commercialization Progress and Semiconductor Industry Shift Toward AI-Driven Environmental Intelligence

Wed, 20 May 2026 08:00:00 -0400

The VASRO report characterizes Ainos' first quarter of 2026 as a "commercialization-build quarter." According to the report, Ainos continues progressing key

Ainos Reports First Quarter 2026 Financial Results and Highlights Smell AI Execution Across Semiconductors and Healthcare Infrastructure Markets

Wed, 13 May 2026 16:30:00 -0400

HOUSTON, TX / ACCESS Newswire / May 13, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced financial results for the first quarter ended March 31, 2026 and provided a business update on recent execution progress for AI Nose across semiconductors and healthcare infrastructure applications .

During the first quarter of 2026, Ainos continued executing its commercialization priorities for AI Nose across industrial infrastructure environments while continuing to expand its Smell ID datasets and refine its Smell Language Model ("SLM") through deployment and pilot activities.

"Our first quarter progress reflects a continued

Ainos Reports First Quarter 2026 Financial Results and Highlights Smell AI Execution Across Semiconductors and Healthcare Infrastructure Markets

Wed, 13 May 2026 16:30:00 -0400

"Our first quarter progress reflects a continued

Ainos Reports First Quarter 2026 Financial Results and Highlights Smell AI Execution Across Semiconductors and Healthcare Infrastructure Markets

Wed, 13 May 2026 16:30:00 -0400

"Our first quarter progress reflects a continued

Ainos Reports First Quarter 2026 Financial Results and Highlights Smell AI Execution Across Semiconductors and Healthcare Infrastructure Markets

Wed, 13 May 2026 16:30:00 -0400

"Our first quarter progress reflects a continued

Ainos changes industry classification code to reflect AI focus

Mon, 11 May 2026 08:03:50 -0400

Ainos Inc. (NASDAQ: AIMD) announced it updated its Standard Industrial Classification code from SIC 2834 - Pharmaceutical Preparations to SIC 3577 - Computer Peripheral Equipment, NEC. The company said the change reflects its operational shift toward AI-powered sensing and scent intelligence technologies.

The Houston-based company develops AI Nose, a platform that converts volatile organic compound and scent signals into machine-readable data using artificial intelligence models and sensor technologies. Ainos is pursuing commercial deployments across semiconductor manufacturing, robotics, smart infrastructure, and healthcare environments.

"The updated industry classification reflects the continued evolution of our business from healthcare-originated applications toward AI-powered sensing and environmental intelligence